GLP-1 vasodilatation in humans with coronary artery disease is not adenosine mediated

BACKGROUND: Incretin therapies appear to provide cardioprotection and improve cardiovascular outcomes in patients with diabetes, but the mechanism of this effect remains elusive. We have previously shown that glucagon-like peptide (GLP)-1 is a coronary vasodilator and we sought to investigate if thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Aetesam-ur-Rahman, Muhammad, Giblett, Joel P., Khialani, Bharat, Kyranis, Stephen, Clarke, Sophie J., Zhao, Tian X., Braganza, Denise M., Clarke, Sarah C., West, Nick E. J., Bennett, Martin R., Hoole, Stephen P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088691/
https://www.ncbi.nlm.nih.gov/pubmed/33932990
http://dx.doi.org/10.1186/s12872-021-02030-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088691/
https://www.ncbi.nlm.nih.gov/pubmed/33932990
http://dx.doi.org/10.1186/s12872-021-02030-5

Ejemplares similares